Study comparing Esomeprazole Magnesium 40mg once daily versus Lansoprazole 30 mg twice daily in symptom control of subjects with persistent gastrooesophageal reflux disease (GERD)
Study identifier:311
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A multi-centred, Phase IV, Post-Marketing, Prospective, Randomized, Double-Blind study comparing Esomeprazole Magnesium 40mg once daily versus Lansoprazole 30 mg twice daily in symptom control of subjects with persistent gastrooesophageal reflux disease while on 30mg once daily lansoprazole therapy
Medical condition
Heartburn
Phase
Phase 4
Healthy volunteers
No
Study drug
Esomeprazole Magnesium, Lansoprazole
Sex
All
Actual Enrollment
248
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jun 2002
Primary Completion Date: 01 Feb 2003
Study Completion Date: 01 Feb 2003
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 40mg once daily | Drug: Esomeprazole Magnesium 40mg once daily Other Name: Nexium |
| Active Comparator: 2 30mg twice daily | Drug: Lansoprazole 30mg twice daily Other Name: Prevacid |
Contacts
Investigators
Principal Investigator
Paula Fernstrom
Nexium Global Product Director, AstraZeneca
